These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 27942454)

  • 1. Acetazolamide-augmented dynamic BOLD (aczBOLD) imaging for assessing cerebrovascular reactivity in chronic steno-occlusive disease of the anterior circulation: An initial experience.
    Wu J; Dehkharghani S; Nahab F; Qiu D
    Neuroimage Clin; 2017; 13():116-122. PubMed ID: 27942454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. White Matter Cerebrovascular Reactivity: Effects of Microangiopathy and Proximal Occlusions on the Dynamic BOLD Response.
    Gee JM; Wang X; Dogra S; Veraart J; Ishida K; Dehkharghani S
    medRxiv; 2023 Jun; ():. PubMed ID: 37398412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuronal activation induced BOLD and CBF responses upon acetazolamide administration in patients with steno-occlusive artery disease.
    Siero JC; Hartkamp NS; Donahue MJ; Harteveld AA; Compter A; Petersen ET; Hendrikse J
    Neuroimage; 2015 Jan; 105():276-85. PubMed ID: 25261002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acetazolamide-augmented BOLD MRI to Assess Whole-Brain Cerebrovascular Reactivity in Chronic Steno-occlusive Disease Using Principal Component Analysis.
    Dogra S; Wang X; Gupta A; Veraart J; Ishida K; Qiu D; Dehkharghani S
    Radiology; 2023 May; 307(3):e221473. PubMed ID: 36916889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical implication and prognosis of normal baseline cerebral blood flow with impaired vascular reserve in patients with major cerebral artery occlusive disease.
    Isozaki M; Arai Y; Kudo T; Kiyono Y; Kobayashi M; Kubota T; Kikuta K; Okazawa H
    Ann Nucl Med; 2010 Jun; 24(5):371-7. PubMed ID: 20238185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BOLD cerebrovascular reactivity as a novel marker for crossed cerebellar diaschisis.
    Sebök M; van Niftrik CHB; Piccirelli M; Bozinov O; Wegener S; Esposito G; Pangalu A; Valavanis A; Buck A; Luft AR; Regli L; Fierstra J
    Neurology; 2018 Oct; 91(14):e1328-e1337. PubMed ID: 30185447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perfusion computed tomography evaluation of cerebral hemodynamic impairment in patients with unilateral chronic steno-occlusive disease: a comparison with the acetazolamide challenge 99mTc-hexamethylpropyleneamine oxime single-photon emission computed tomography.
    Kim E; Sohn CH; Na DG; Kim JE; Chang KH; Kim JH; Jeon SJ
    J Comput Assist Tomogr; 2009; 33(4):546-51. PubMed ID: 19638847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can the detection of misery perfusion in chronic cerebrovascular disease be based on reductions in baseline CBF and vasoreactivity?
    Okazawa H; Tsuchida T; Kobayashi M; Arai Y; Pagani M; Isozaki M; Yonekura Y
    Eur J Nucl Med Mol Imaging; 2007 Jan; 34(1):121-9. PubMed ID: 16896662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Staging Hemodynamic Failure With Blood Oxygen-Level-Dependent Functional Magnetic Resonance Imaging Cerebrovascular Reactivity: A Comparison Versus Gold Standard (
    Fierstra J; van Niftrik C; Warnock G; Wegener S; Piccirelli M; Pangalu A; Esposito G; Valavanis A; Buck A; Luft A; Bozinov O; Regli L
    Stroke; 2018 Mar; 49(3):621-629. PubMed ID: 29371433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mapping cerebrovascular reactivity using blood oxygen level-dependent MRI in Patients with arterial steno-occlusive disease: comparison with arterial spin labeling MRI.
    Mandell DM; Han JS; Poublanc J; Crawley AP; Stainsby JA; Fisher JA; Mikulis DJ
    Stroke; 2008 Jul; 39(7):2021-8. PubMed ID: 18451352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemodynamic Failure Staging With Blood Oxygenation Level-Dependent Cerebrovascular Reactivity and Acetazolamide-Challenged (
    Sebök M; van der Wouden F; Mader C; Pangalu A; Treyer V; Fisher JA; Mikulis DJ; Hüllner M; Regli L; Fierstra J; van Niftrik CHB
    J Am Heart Assoc; 2023 Dec; 12(24):e029491. PubMed ID: 38084716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resting-state Functional Magnetic Resonance Imaging Identifies Cerebrovascular Reactivity Impairment in Patients With Arterial Occlusive Diseases: A Pilot Study.
    Nishida S; Aso T; Takaya S; Takahashi Y; Kikuchi T; Funaki T; Yoshida K; Okada T; Kunieda T; Togashi K; Fukuyama H; Miyamoto S
    Neurosurgery; 2019 Nov; 85(5):680-688. PubMed ID: 30247676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced contralateral cerebrovascular reserve in patients with unilateral steno-occlusive disease.
    Sam K; Small E; Poublanc J; Han JS; Mandell DM; Fisher JA; Crawley AP; Mikulis DJ
    Cerebrovasc Dis; 2014; 38(2):94-100. PubMed ID: 25277683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acetazolamide-challenged perfusion magnetic resonance imaging for assessment of cerebrovascular reserve capacity in patients with symptomatic middle cerebral artery stenosis: comparison with technetium-99m-hexamethylpropyleneamine oxime single-photon emission computed tomography.
    Kim HJ; Kim TW; Ryu SY; Yang PS; Kwon MJ; Kim JC; Lee YS; Lee HJ; Yang JH; Kim JK; Chung YA; Oh EY; Lee SB
    Clin Imaging; 2011; 35(6):413-20. PubMed ID: 22040783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accuracy of central benzodiazepine receptor binding potential/cerebral blood flow SPECT imaging for detecting misery perfusion in patients with unilateral major cerebral artery occlusive diseases: comparison with cerebrovascular reactivity to acetazolamide and cerebral blood flow SPECT imaging.
    Kuroda H; Ogasawara K; Suzuki T; Chida K; Aso K; Kobayashi M; Yoshida K; Terasaki K; Fujiwara S; Kubo Y; Ogawa A
    Clin Nucl Med; 2012 Mar; 37(3):235-40. PubMed ID: 22310248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between vasodilatation and cerebral blood flow increase in impaired hemodynamics: a PET study with the acetazolamide test in cerebrovascular disease.
    Okazawa H; Yamauchi H; Toyoda H; Sugimoto K; Fujibayashi Y; Yonekura Y
    J Nucl Med; 2003 Dec; 44(12):1875-83. PubMed ID: 14660711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in vasodilatory capacity and changes in cerebral blood flow induced by acetazolamide in patients with cerebrovascular disease.
    Okazawa H; Yamauchi H; Sugimoto K; Takahashi M
    J Nucl Med; 2003 Sep; 44(9):1371-8. PubMed ID: 12960179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of cerebrovascular reserve using xenon-enhanced CT scanning in patients with symptomatic middle cerebral artery stenosis.
    Cao W; Cheng X; Li H; Wang L; Zhang X; Dong Q
    J Clin Neurosci; 2014 Feb; 21(2):293-7. PubMed ID: 24238634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebral MR oximetry during acetazolamide augmentation: Beyond cerebrovascular reactivity in hemodynamic failure.
    Leatherday C; Dehkharghani S; Nahab F; Allen JW; Wu J; Hu R; Qiu D
    J Magn Reson Imaging; 2019 Jul; 50(1):175-182. PubMed ID: 30390367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of combination therapy with the angiotensin receptor blocker losartan plus hydrochlorothiazide on brain perfusion in patients with both hypertension and cerebral hemodynamic impairment due to symptomatic chronic major cerebral artery steno-occlusive disease: a SPECT study.
    Saura H; Ogasawara K; Suzuki T; Kuroda H; Yamashita T; Kobayashi M; Terasaki K; Ogawa A
    Cerebrovasc Dis; 2012; 33(4):354-61. PubMed ID: 22433127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.